AliveCor announced today that it received FDA clearance for the next generation of its AI technology for the Kardia 12L ECG ...
Medical Device Network on MSN
AliveCor secures FDA approval for next-generation Kardia 12L ECG system
The newly cleared features include three rhythm modifiers and two axis-related morphology determinations: RAD and LAD.
The ECG shows an irregularly irregular rapid ventricular rate, approximately 120 beats per minute, with no visible P waves. The frontal plane QRS axis is –30° and the R wave voltage in AVL is 15 mV.
The ECG shows sinus tachycardia at about 115 beats per minute with a PR interval of about 0.15 sec (normal). The P waves show normal duration, but they are peaked in II, II and AVF and their amplitude ...
Background Interpretation of the athlete’s ECG is based on differentiation between benign ECG changes and potentially pathological abnormalities. The aim of the study was to compare the 2010 European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results